Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763707 | PMC |
http://dx.doi.org/10.4103/0019-5154.174040 | DOI Listing |
QJM
December 2024
Assistant Professor, All India Institute of Medical Sciences, Delhi, 110029, India.
Cureus
November 2024
Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Scleromyxedema, a rare skin condition, is characterized by a waxy-appearing papular eruption that tends to impact middle-aged adults. Scleromyxedema is often linked to monoclonal gammopathies. However, some patients do not have a coinciding monoclonal gammopathy and experience an atypical presentation of the disease.
View Article and Find Full Text PDFJ Clin Apher
December 2024
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Scleromyxedema is a rare skin mucinosis often associated with systemic involvement and monoclonal gammopathy (MG). No formal recommendation for management with therapeutic plasma exchange (TPE) has been published due to rarity. This paper reports a 42-year-old male with progressive scleromyxedema.
View Article and Find Full Text PDFCase Rep Dermatol
August 2024
Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: We provide a case report on a patient with scleromyxedema treated with high-dose intravenous immunoglobulins (IVIgs) who reported less fatigue and fewer headaches after transitioning to Yimmugo, a novel IVIg preparation. Scleromyxedema is a rare and chronic cutaneous mucinosis, frequently associated with monoclonal gammopathy and systemic complications, which may be life-threatening. The disease is characterized by papular eruptions and sclerosis of the skin.
View Article and Find Full Text PDFJAAD Case Rep
November 2024
Department of Dermatology, McGaw Medical Center of Northwestern University, Chicago, Illinois.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!